Apriso belongs to a group of medications called aminosalicylates. It is thought that Apriso works by inhibiting the production of inflammatory chemicals in the lining of the colon. It decreases the production of prostaglandins and leukotrienes, chemicals that lead to the inflammation of ulcerative colitis.
Apriso capsules are extended-release, which allows them to be taken just once daily. They are also delayed-release, designed to delay the release of the medication until it passes through the stomach (allowing the medication to be released in the small and large intestines).
Apriso has not been approved for ulcerative colitis in children. Be sure to talk with your healthcare provider about the risks and benefits of using Apriso in children.
On occasion, your healthcare provider may recommend Apriso for something other than ulcerative colitis. This is called an "off-label" use. At this time, using Apriso to treat Crohn's disease is considered an off-label use.